UY38986A - Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas - Google Patents
Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticasInfo
- Publication number
- UY38986A UY38986A UY0001038986A UY38986A UY38986A UY 38986 A UY38986 A UY 38986A UY 0001038986 A UY0001038986 A UY 0001038986A UY 38986 A UY38986 A UY 38986A UY 38986 A UY38986 A UY 38986A
- Authority
- UY
- Uruguay
- Prior art keywords
- diona
- metoxy
- oxoisoindolin
- piperidin
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente divulgación se relaciona con composiciones farmacéuticas y compuestos de fórmula (I) y con su uso para reducir los niveles de expresión de los Motivos de Dedos de Zinc Ampliamente Interespaciados (WIZ), o para inducir la expresión de la hemoglobina fetal (HbF), y para el tratamiento de trastornos sanguíneos hereditarios (hemoglobinopatías, por ejemplo, beta-hemoglobinopatías), tales como la enfermedad de células falciformes y la beta-talasemia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962950048P | 2019-12-18 | 2019-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38986A true UY38986A (es) | 2021-07-30 |
Family
ID=73856242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038986A UY38986A (es) | 2019-12-18 | 2020-12-16 | Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas |
Country Status (21)
Country | Link |
---|---|
US (1) | US11566022B2 (es) |
EP (1) | EP4076650B1 (es) |
JP (1) | JP2023506642A (es) |
KR (1) | KR20220114065A (es) |
CN (1) | CN114828959B (es) |
AR (1) | AR120773A1 (es) |
AU (1) | AU2020410514A1 (es) |
BR (1) | BR112022011796A2 (es) |
CA (1) | CA3164832A1 (es) |
CO (1) | CO2022008243A2 (es) |
CR (1) | CR20220278A (es) |
DO (1) | DOP2022000121A (es) |
EC (1) | ECSP22055267A (es) |
ES (1) | ES2980575T3 (es) |
IL (1) | IL293530A (es) |
JO (1) | JOP20220152A1 (es) |
MX (1) | MX2022007351A (es) |
PE (1) | PE20230159A1 (es) |
TW (1) | TW202130631A (es) |
UY (1) | UY38986A (es) |
WO (1) | WO2021124172A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023536657A (ja) * | 2020-08-07 | 2023-08-28 | コーネル ユニバーシティー | タンパク質をe3リガーゼの媒介によって分解するための、治療上有用なcure-pro分子、ならびにその作製方法及び使用方法 |
UY39671A (es) | 2021-03-15 | 2022-10-31 | Novartis Ag | Derivados de pirazolopiridina y sus usos. |
CA3215410A1 (en) * | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
JP2024528143A (ja) * | 2021-07-30 | 2024-07-26 | ヒノバ ファーマシューティカルズ インコーポレイテッド | 二官能性キメラ複素環式化合物及びアンドロゲン受容体分解剤としての使用 |
WO2024140638A1 (zh) * | 2022-12-27 | 2024-07-04 | 标新生物医药科技(上海)有限公司 | 基于硫/氧取代戊二酰亚胺基异吲哚啉酮骨架的化合物及其应用 |
CN115959976A (zh) * | 2022-12-30 | 2023-04-14 | 安徽诺全药业有限公司 | 一种甲氧基取代双环戊烷衍生物的制备方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW589189B (en) | 1997-08-04 | 2004-06-01 | Scras | Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
JP2004532616A (ja) | 2000-12-28 | 2004-10-28 | ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド | 二本鎖rna仲介遺伝子抑制 |
JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
RS58523B1 (sr) | 2010-02-11 | 2019-04-30 | Celgene Corp | Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe |
JP2013543009A (ja) | 2010-11-18 | 2013-11-28 | デューテリア ファーマシューティカルズ, インコーポレイテッド | 3−ジュウテロ−ポマリドマイド |
WO2012079022A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
US9133161B2 (en) | 2012-07-27 | 2015-09-15 | Celgene Corporation | Processes for preparing isoindoline-1,3-dione compounds |
US20170038387A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
AU2017254708B2 (en) | 2016-04-22 | 2021-09-16 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use |
WO2018071606A1 (en) | 2016-10-11 | 2018-04-19 | Arvinas, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
US11458123B2 (en) | 2016-11-01 | 2022-10-04 | Arvinas Operations, Inc. | Tau-protein targeting PROTACs and associated methods of use |
EP3689868B1 (en) | 2016-12-01 | 2023-09-27 | Arvinas Operations, Inc. | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders |
CA3047784A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES |
BR112019012682A2 (pt) | 2016-12-23 | 2019-12-17 | Arvinas Operations Inc | moléculas quiméricas visando a proteólise de egfr e métodos associados de uso |
US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
KR20230140606A (ko) | 2017-01-26 | 2023-10-06 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법 |
TW202428622A (zh) * | 2017-10-18 | 2024-07-16 | 瑞士商諾華公司 | 用於選擇性蛋白質降解的組合物及方法 |
US11505560B2 (en) | 2017-10-20 | 2022-11-22 | Dana-Farber Cancer Institute, Inc. | Heterobifunctional compounds with improved specificity |
US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
US11028088B2 (en) | 2018-03-10 | 2021-06-08 | Yale University | Modulators of BTK proteolysis and methods of use |
WO2019191112A1 (en) * | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
CN112218859A (zh) | 2018-04-04 | 2021-01-12 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
US12030892B2 (en) | 2018-06-29 | 2024-07-09 | Dana-Farber Cancer Institute, Inc. | CRBN modulators |
US12060366B2 (en) | 2018-06-29 | 2024-08-13 | Dana-Farber Cancer Institute, Inc. | Bispecific degraders |
CA3102212A1 (en) | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
KR20210025061A (ko) | 2018-06-29 | 2021-03-08 | 다나-파버 캔서 인스티튜트 인크. | 세레블론(crbn)에 대한 리간드 |
WO2020117759A1 (en) | 2018-12-03 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of helios and methods of use |
-
2020
- 2020-12-16 CR CR20220278A patent/CR20220278A/es unknown
- 2020-12-16 PE PE2022001098A patent/PE20230159A1/es unknown
- 2020-12-16 CN CN202080087049.9A patent/CN114828959B/zh active Active
- 2020-12-16 EP EP20828350.7A patent/EP4076650B1/en active Active
- 2020-12-16 AR ARP200103501A patent/AR120773A1/es unknown
- 2020-12-16 ES ES20828350T patent/ES2980575T3/es active Active
- 2020-12-16 UY UY0001038986A patent/UY38986A/es unknown
- 2020-12-16 BR BR112022011796A patent/BR112022011796A2/pt not_active Application Discontinuation
- 2020-12-16 AU AU2020410514A patent/AU2020410514A1/en not_active Abandoned
- 2020-12-16 US US17/124,127 patent/US11566022B2/en active Active
- 2020-12-16 JP JP2022537250A patent/JP2023506642A/ja active Pending
- 2020-12-16 CA CA3164832A patent/CA3164832A1/en active Pending
- 2020-12-16 TW TW109144481A patent/TW202130631A/zh unknown
- 2020-12-16 MX MX2022007351A patent/MX2022007351A/es unknown
- 2020-12-16 IL IL293530A patent/IL293530A/en unknown
- 2020-12-16 KR KR1020227024287A patent/KR20220114065A/ko active Search and Examination
- 2020-12-16 WO PCT/IB2020/062070 patent/WO2021124172A1/en active Application Filing
- 2020-12-16 JO JOP/2022/0152A patent/JOP20220152A1/ar unknown
-
2022
- 2022-06-13 CO CONC2022/0008243A patent/CO2022008243A2/es unknown
- 2022-06-14 DO DO2022000121A patent/DOP2022000121A/es unknown
- 2022-07-14 EC ECSENADI202255267A patent/ECSP22055267A/es unknown
Also Published As
Publication number | Publication date |
---|---|
ES2980575T3 (es) | 2024-10-02 |
JOP20220152A1 (ar) | 2023-01-30 |
CN114828959B (zh) | 2024-04-02 |
DOP2022000121A (es) | 2022-08-15 |
IL293530A (en) | 2022-08-01 |
CR20220278A (es) | 2022-07-01 |
EP4076650A1 (en) | 2022-10-26 |
WO2021124172A1 (en) | 2021-06-24 |
PE20230159A1 (es) | 2023-02-01 |
JP2023506642A (ja) | 2023-02-17 |
BR112022011796A2 (pt) | 2022-08-30 |
TW202130631A (zh) | 2021-08-16 |
CA3164832A1 (en) | 2021-06-24 |
AU2020410514A1 (en) | 2022-06-30 |
US11566022B2 (en) | 2023-01-31 |
ECSP22055267A (es) | 2022-08-31 |
KR20220114065A (ko) | 2022-08-17 |
MX2022007351A (es) | 2022-07-19 |
US20220402904A1 (en) | 2022-12-22 |
AR120773A1 (es) | 2022-03-16 |
CN114828959A (zh) | 2022-07-29 |
EP4076650B1 (en) | 2024-02-28 |
CO2022008243A2 (es) | 2022-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38986A (es) | Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas | |
EA201792421A1 (ru) | Амидозамещенные производные циклогексана | |
CL2017003245A1 (es) | Derivados de piperidina 1,4-sustituidos | |
GEP20217316B (en) | Aromatic sulfonamide derivatives | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
BR112012023421A2 (pt) | composição farmacêutica para tratamento de aumento de pressão intraocular | |
EA202090448A1 (ru) | Дигидрооксадиазиноны | |
EA201201661A1 (ru) | Новые аминопиразолохиназолины | |
BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
ATE530524T1 (de) | Substituierte sulfonamid-derivate | |
BR112014017780A8 (pt) | Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos | |
EA201390010A1 (ru) | Замещенные триазолопиридины | |
BR112017010592A2 (pt) | análogos de ureia ligados em ponte substituídos como moduladores de sirtuína | |
EA201691881A1 (ru) | Новые соединения | |
EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена | |
EA201590562A1 (ru) | Бензамиды | |
EA201891710A1 (ru) | Терапевтические соединения | |
CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
CA2904533C (en) | Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells | |
ECSP21088111A (es) | Analogos de 3(5metil1,3tiazol2il)n{(1r)1[2(trifluormetil)pirimidin5il]etil}benzamida | |
EA201501175A1 (ru) | Новые соединения для лечения злокачественного новообразования | |
CO2024000013A2 (es) | Derivados de 3–(1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos médicos | |
EA201691878A1 (ru) | ИНГИБИТОРЫ СИГНАЛЬНЫХ ПУТЕЙ Wnt | |
CY1123360T1 (el) | Ενωσεις oi οποιες εχουν αντιοξειδωτικη δραση εναντι των ελευθερων ριζων και αντιφλεγμονωδη δραση, και αντιστοιχες φαρμακευτικες συνθεσεις για τη φροντιδα του δερματος | |
BR112021019876A2 (pt) | Inibidores de pde9 para tratar anemia falciforme |